Social Media Ideas for Alkermes Inc

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Alkermes Must Face Bulk Of Addiction Treatment Drug Suit

A Massachusetts federal judge largely refused Thursday to let Alkermes duck a proposed class action alleging it tricked the U.S. Patent and Trademark Office into granting a patent...

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

The insider still has significant holdings in the company, signaling confidence.

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

<![CDATA[Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeut...

Alkem Laboratories launches NeuCeno for partial-onset seizures in adults

The once-daily oral therapy is available in five strengths, with clinical studies showing reductions in seizure frequency among adults with uncontrolled focal seizures

Revolution Medicines

Revolution Medicines Anonymous (not verified) Wed, 09/30/2026 - 01:04 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

<![CDATA[Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Ente...

<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>

<![CDATA[METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies]]&gt...

Pharmacosmos Therapeutics

Pharmacosmos Therapeutics Anonymous (not verified) Fri, 10/16/2026 - 10:12 field_thread_url https://cafepharma.com/boards/threads/pharmacosmos-therapeutics...

<![CDATA[Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roc...

Broker’s Call: Alkem Laboratories (Buy)

Elara Securities

Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bis...

HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved reco...

Kiniksa

Kiniksa Anonymous (not verified) Mon, 10/05/2026 - 04:07 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Roche Puts Up $100M to Pursue Promising But Competitive New Target in Obesity

Roche gains global rights to a Rona Therapeutics RNA interference drug designed to target ALK7, a genetically validated target for obesity and other metabolic indications. The grow...

Kiniksa

Kiniksa Anonymous (not verified) Thu, 09/17/2026 - 18:54 field_thread_url https://cafepharma.com/boards/threads/kiniksa.658756/ board na...

Alkane Resources Ltd (ALK:CA) Presents at Mining Forum Americas 2026 - Slideshow

<![CDATA[Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM ]]>